A Study of Atezolizumab and Trastuzumab in Combination With Capecitabine and Oxaliplatin in Patients With HER2 Positive Locally Advanced Resectable Gastric Cancer of Adenocarcinoma of Gastroesophageal Junction
Hoffmann-La Roche
Hoffmann-La Roche
Institut Cancerologie de l'Ouest
Baylor College of Medicine
Yale University
Seagen Inc.
University Hospital, Akershus
Memorial Sloan Kettering Cancer Center
OHSU Knight Cancer Institute
Providence Health & Services
National Cancer Institute (NCI)
Dana-Farber Cancer Institute
Nationwide Children's Hospital
Leap Therapeutics, Inc.
Institut Bergonié
Ohio State University Comprehensive Cancer Center
Dana-Farber Cancer Institute
Bruckner Oncology
Asan Medical Center
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Bristol-Myers Squibb
Federation Francophone de Cancerologie Digestive
Merck Sharp & Dohme LLC
Hoosier Cancer Research Network
Kyowa Kirin Co., Ltd.
NSABP Foundation Inc
Big Ten Cancer Research Consortium
Jiangsu HengRui Medicine Co., Ltd.
Hoosier Cancer Research Network
Herlev Hospital
Albert Einstein College of Medicine
University of Nebraska
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
University of Nebraska
University of California, Irvine
Medical College of Wisconsin
University of Cincinnati
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
Brown University
M.D. Anderson Cancer Center
Alliance for Clinical Trials in Oncology
Memorial Sloan Kettering Cancer Center
Yale University
SWOG Cancer Research Network
Ipsen
Fox Chase Cancer Center
Molecular Templates, Inc.
Brown University
Dana-Farber Cancer Institute
Indiana University